Brind.
  1. Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
  2. Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
  3. Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
  4. Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.

Mounjaro's approval caused a decline in Trulicity sales, marking a specific development in the weight loss drug market.

2 reports, 1 independent Updated Aug 21
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Mounjaro's approval caused a decline in Trulicity sales, marking a specific development in the weight loss drug market.

Who's involved

What this event is mainly about
Eli Lilly and CompanyNovo Nordisk

Keep exploring

Part of

Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.

Also in this story

All 5 developments

Within Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Pharma VoiceThe biggest Big Pharma losers in the first half of 2025 This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The
  • Unknown outlet